MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$19,578,000
EPS
-$0.25
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Collaboration revenue
0 0 0 0
Restructuring expenses
0 0 0 -
Research and development
14,084,000 15,416,000 14,296,000 12,987,000
General and administrative
8,102,000 7,277,000 7,562,000 6,828,000
Total operating expenses
22,186,000 22,693,000 21,858,000 19,815,000
Loss from operations
-22,186,000 -22,693,000 -21,858,000 -19,815,000
Other income, net
3,295,000 2,359,000 2,263,000 2,519,000
Net (loss) income
-18,891,000 -20,334,000 -19,595,000 -17,296,000
Unrealized loss on marketable securities
-687,000 -115,000 159,000 -
Total other comprehensive loss
-687,000 -115,000 159,000 -
Comprehensive (loss) income
-19,578,000 -20,449,000 -19,436,000 -
Basic EPS
-0.25 0.109 -0.31 -0.28
Diluted EPS
-0.25 0.109 -0.31 -0.28
Basic Average Shares
76,215,000 -187,366,580 62,597,000 62,544,000
Diluted Average Shares
76,215,000 -187,366,580 62,597,000 62,544,000
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive (loss) income-$19,578,000 Net (loss) income-$18,891,000 (-7.00%↓ Y/Y)Total othercomprehensive loss-$687,000 Other income, net$3,295,000 (19.91%↑ Y/Y)Loss from operations-$22,186,000 (-8.74%↓ Y/Y)Unrealized loss onmarketable securities-$687,000 Total operatingexpenses$22,186,000 (8.74%↑ Y/Y)Research and development$14,084,000 (5.07%↑ Y/Y)General andadministrative$8,102,000 (15.76%↑ Y/Y)

Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. (FULC)